Cargando…
A Comparative Study of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration: 12-Month Outcomes of Polish Therapeutic Program in Non-Tertiary Institution
Introduction This single-center study aimed to compare the 12-month treatment outcomes of ranibizumab with that of aflibercept in routine clinical practice. Methods Cohort of patients diagnosed with treatment-naïve neovascular age-related macular degeneration (AMD), treated using either ranibizumab...
Autores principales: | Skrzypczak, Tomasz, Jany, Aleksandra, Bugajska-Abramek, Ewa, Bogusławska, Joanna, Kowal-Lange, Agnieszka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312781/ https://www.ncbi.nlm.nih.gov/pubmed/34336421 http://dx.doi.org/10.7759/cureus.15916 |
Ejemplares similares
-
Publication Times in Ophthalmology Journals: The Story of Accepted Manuscripts
por: Skrzypczak, Tomasz, et al.
Publicado: (2021) -
Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021) -
Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration
por: Dikmetas, Ozlem, et al.
Publicado: (2022) -
Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials
por: Zhao, Xinyu, et al.
Publicado: (2021) -
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020)